PDF(Pubmed)
Abstract：
BACKGROUND: Clinical practice guidelines (CPGs) offer disease management recommendations based on scientific evidence. However, financial conflicts of interest between CPG developers and the pharmaceutical industry could bias these recommendations, potentially affecting patient care. Proper management of these conflicts of interest is particularly crucial for maintaining the integrity of CPGs. The study aimed to evaluate the extent of financial relationships between the pharmaceutical industry and authors of CPGs for cardiovascular diseases in Japan.
RESULTS: The study analyzed personal payments from the pharmaceutical industry to authors of cardiovascular disease CPGs published by the Japanese Circulation Society from January 2015 to December 2022. Payment data, including speaking, consultancy, and writing fees from 2016 to 2020, were extracted from a publicly available database containing personal payments disclosed by all major pharmaceutical companies. A total of 929 unique authors from 37 eligible Japanese Circulation Society CPGs were identified. Notably, 94.4% of these authors received personal payments from pharmaceutical companies, totaling >US $70.8 million. The mean±SD payment per author was US $76 314±138 663) and the median payment per author was US $20 792 (interquartile range: US $4262-US $76 998) over the 5-year period. Chairs of CPGs received significantly higher payments than other authors. More than 80% of authors in each CPG received personal payments.
CONCLUSIONS: The study elucidated that there were considerable financial relationships between pharmaceutical companies and cardiology CPG authors in Japan. This finding deviates from international conflict of interest management policies, suggesting the need for more stringent conflict of interest management strategies by the Japanese Circulation Society to ensure the development of trustworthy and evidence-based CPGs.
RESULTS: The study analyzed personal payments from the pharmaceutical industry to authors of cardiovascular disease CPGs published by the Japanese Circulation Society from January 2015 to December 2022. Payment data, including speaking, consultancy, and writing fees from 2016 to 2020, were extracted from a publicly available database containing personal payments disclosed by all major pharmaceutical companies. A total of 929 unique authors from 37 eligible Japanese Circulation Society CPGs were identified. Notably, 94.4% of these authors received personal payments from pharmaceutical companies, totaling >US $70.8 million. The mean±SD payment per author was US $76 314±138 663) and the median payment per author was US $20 792 (interquartile range: US $4262-US $76 998) over the 5-year period. Chairs of CPGs received significantly higher payments than other authors. More than 80% of authors in each CPG received personal payments.
CONCLUSIONS: The study elucidated that there were considerable financial relationships between pharmaceutical companies and cardiology CPG authors in Japan. This finding deviates from international conflict of interest management policies, suggesting the need for more stringent conflict of interest management strategies by the Japanese Circulation Society to ensure the development of trustworthy and evidence-based CPGs.
摘要：
背景：临床实践指南（CPGs）基于科学证据提供疾病管理建议。然而,CPG开发商和制药业之间的财务利益冲突可能会偏向这些建议，可能影响患者护理。适当管理这些利益冲突对于保持CPG的完整性尤为重要。该研究旨在评估日本制药业与心血管疾病CPG作者之间的财务关系程度。
结果：该研究分析了2015年1月至2022年12月日本循环学会发布的从制药业向心血管疾病CPG作者的个人支付。付款数据,包括说话,咨询,以及2016年至2020年的写作费用，均从包含所有主要制药公司披露的个人付款的公开数据库中提取。从37名合格的日本流通协会CPG中总共确定了929名独特作者。值得注意的是,这些作者中有94.4%收到了制药公司的个人付款，总计>7080万美元。在5年内，每位作者的平均±SD付款额为76314±138663美元），每位作者的平均付款额为20792美元（四分位距：4262美元-76998美元）。CPG主席收到的报酬明显高于其他作者。每个CPG中超过80％的作者都收到了个人付款。
结论：研究表明，日本的制药公司与心脏病学CPG作者之间存在相当大的财务关系。这一发现偏离了国际利益冲突管理政策，建议日本流通协会需要采取更严格的利益冲突管理策略，以确保开发值得信赖和基于证据的CPG。
结果：该研究分析了2015年1月至2022年12月日本循环学会发布的从制药业向心血管疾病CPG作者的个人支付。付款数据,包括说话,咨询,以及2016年至2020年的写作费用，均从包含所有主要制药公司披露的个人付款的公开数据库中提取。从37名合格的日本流通协会CPG中总共确定了929名独特作者。值得注意的是,这些作者中有94.4%收到了制药公司的个人付款，总计>7080万美元。在5年内，每位作者的平均±SD付款额为76314±138663美元），每位作者的平均付款额为20792美元（四分位距：4262美元-76998美元）。CPG主席收到的报酬明显高于其他作者。每个CPG中超过80％的作者都收到了个人付款。
结论：研究表明，日本的制药公司与心脏病学CPG作者之间存在相当大的财务关系。这一发现偏离了国际利益冲突管理政策，建议日本流通协会需要采取更严格的利益冲突管理策略，以确保开发值得信赖和基于证据的CPG。
